You just read:

TREMFYA® (guselkumab), a First-in-Class IL-23 p19 Subunit Inhibitor, Meets Primary Endpoints of Superior ACR20 Responses versus Placebo at Week 24 in Phase 3 Psoriatic Arthritis Studies

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Nov 11, 2019, 08:00 ET